Annovis Bio, Inc. (ANVS)

USD 4.71

(-7.83%)

Total Liabilities Summary of Annovis Bio, Inc.

Annovis Bio, Inc.'s latest annual total liabilities in 2023 was 17.95 Million USD , up 133.28% from previous year.
Annovis Bio, Inc.'s latest quarterly total liabilities in 2024 Q2 was 6.79 Million USD , down -39.13% from previous quarter.
Annovis Bio, Inc. reported annual total liabilities of 7.69 Million USD in 2022, up 411.02% from previous year.
Annovis Bio, Inc. reported annual total liabilities of 1.5 Million USD in 2021, up 160.47% from previous year.
Annovis Bio, Inc. reported quarterly total liabilities of 11.16 Million USD for 2024 Q1, down -37.82% from previous quarter.
Annovis Bio, Inc. reported quarterly total liabilities of 17.95 Million USD for 2023 Q4, up 403.78% from previous quarter.

Annual Total Liabilities Chart of Annovis Bio, Inc. (2023 - 2017)

Historical Annual Total Liabilities of Annovis Bio, Inc. (2023 - 2017)

Year	Total Liabilities	Total Liabilities Growth
2023	17.95 Million USD	133.28%
2022	7.69 Million USD	411.02%
2021	1.5 Million USD	160.47%
2020	578.38 Thousand USD	-94.03%
2019	9.69 Million USD	26.8%
2018	7.64 Million USD	4.39%
2017	7.32 Million USD	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	6.79 Million USD	-39.13%
2024 Q1	11.16 Million USD	-37.82%
2023 Q4	17.95 Million USD	403.78%
2023 Q2	2.07 Million USD	-61.68%
2023 FY	17.95 Million USD	133.28%
2023 Q1	5.41 Million USD	-29.71%
2023 Q3	3.56 Million USD	71.9%
2022 Q3	2.52 Million USD	94.44%
2022 Q1	1.25 Million USD	-16.6%
2022 FY	7.69 Million USD	411.02%
2022 Q4	7.69 Million USD	204.71%
2022 Q2	1.29 Million USD	3.42%
2021 Q4	1.5 Million USD	34.44%
2021 Q2	884.07 Thousand USD	-44.63%
2021 FY	1.5 Million USD	160.47%
2021 Q1	1.59 Million USD	176.06%
2021 Q3	1.12 Million USD	26.75%
2020 Q1	749.29 Thousand USD	-92.27%
2020 Q3	281.05 Thousand USD	-60.02%
2020 Q4	578.38 Thousand USD	105.79%
2020 FY	578.38 Thousand USD	-94.03%
2020 Q2	702.93 Thousand USD	-6.19%
2019 Q1	8.2 Million USD	7.36%
2019 Q2	8.42 Million USD	2.61%
2019 Q3	8.75 Million USD	3.96%
2019 Q4	9.69 Million USD	10.72%
2019 FY	9.69 Million USD	26.8%
2018 Q1	- USD	0.0%
2018 FY	7.64 Million USD	4.39%
2018 Q4	7.64 Million USD	0.0%
2017 FY	7.32 Million USD	0.0%

Peer Total Liabilities Comparison of Annovis Bio, Inc.

Name	Total Liabilities	Total Liabilities Difference
ADC Therapeutics SA	503.03 Million USD	96.43%
Alto Neuroscience, Inc.	158.3 Million USD	88.655%
Biohaven Pharmaceutical Holding Company Ltd.	85.23 Million USD	78.93%
Ginkgo Bioworks Holdings, Inc.	568.19 Million USD	96.839%
Nuvation Bio Inc.	16.36 Million USD	-9.761%
Nuvation Bio Inc.	16.36 Million USD	-9.761%
Arcus Biosciences, Inc.	633 Million USD	97.163%
Theriva Biologics, Inc.	20.51 Million USD	12.454%
Zymeworks Inc.	116.07 Million USD	84.528%